Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

1. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Comparative Effectiveness Review Number 218 RComparative Effectiveness Review Number 218 Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 (...) . Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19-EHC016-EF April 2019 ii Key Messages Purpose of Review To summarize the effects of long-term osteoporosis drug treatment and of osteoporosis drug treatment discontinuation and holidays. Key Messages • Evidence on the effects of long-term osteoporosis drug treatment and drug continuation versus discontinuation is mostly limited to white, healthy, postmenopausal women. • Long-term alendronate reduces radiographic vertebral and nonvertebral fractures

2019 Effective Health Care Program (AHRQ)

3. Osteoporosis

Osteoporosis Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

4. Osteoporosis

Osteoporosis Top results for osteoporosis - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for osteoporosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

5. Pharmacological Management of Osteoporosis in Postmenopausal Women Full Text available with Trip Pro

Pharmacological Management of Osteoporosis in Postmenopausal Women We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite (...) Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation May 2019 Article Contents Article Navigation Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline Richard Eastell University of Sheffield, Sheffield, United Kingdom Search for other works by this author on: Clifford J Rosen Maine Medical Center Research Institute, Scarborough, Maine Correspondence: Clifford J. Rosen, MD

2019 The Endocrine Society

6. Diagnosis and treatment of osteoporosis.

Diagnosis and treatment of osteoporosis. Diagnosis and treatment of osteoporosis. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested (...) * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011292 2017 Jul NEATS Assessment Diagnosis and treatment of osteoporosis. Allen S, Forney-Gorman A, Homan M, Kearns A, Kramlinger A, Sauer M. Diagnosis and treatment of osteoporosis. Bloomington

2017 National Guideline Clearinghouse (partial archive)

7. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 22 (Suppl 4) September 2016 1 AACE/ACE Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016 Pauline M. Camacho, MD, FACE; Steven M. Petak, MD, MACE (...) University Osteoporosis and Metabolic Bone Disease Center, Chicago, IL; 2 Associate Clinical Professor Weill-Cornell Medical College, Division Head Endocrinology and Chief of Endocrinology, Houston Methodist Hospital, Houston, TX; 3 School of Medicine and Public Health, University of Wisconsin, Madison, WI; 4 Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN; 5 Clinical Professor of Medicine, University of California, San Francisco; 6 Division of Endocrinology

2016 American Association of Clinical Endocrinologists

8. Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. Full Text available with Trip Pro

Statin use is associated with decreased osteoporosis and fracture risks in stroke patients. Poststroke osteoporosis and consequent fractures increase the risk of morbidity and mortality and cause considerable socioeconomic burden.To evaluate the association between statin use and risks of osteoporosis and fracture in stroke patients.Population-based propensity score‒matched cohort study.Taiwan's National Health Insurance Research Database.Patients newly diagnosed with a stroke between 2000 (...) and 2012 were identified. After propensity score matching, 5254 patients were included, with 2627 patients in the statin and nonstatin cohorts, respectively.Hazard ratios (HRs) for poststroke osteoporosis, hip fracture, and vertebral fracture (together, the primary outcome) were calculated using Cox proportional hazards regression models according to statin use status.Poststroke statin use was associated with a lower overall risk of the primary outcome [adjusted hazard ratio (aHR) = 0.66; P < 0.001

2018 Journal of Clinical Endocrinology and Metabolism

9. Denosumab (Prolia) and osteoporosis: an increasingly unfavourable harm-benefit balance

Denosumab (Prolia) and osteoporosis: an increasingly unfavourable harm-benefit balance Prescrire IN ENGLISH - Spotlight ''Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance '', 1 November 2018 {1} {1} {1} | | > > > Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |    (...) |   |   |  Spotlight Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance Reports of sometimes serious adverse effects tilt the harm-benefit balance of denosumab in the treatment of osteoporosis. Denosumab is authorised in some cases of osteoporosis and bone metastases. As expected from the pre-market evaluation of denosumab, reports of adverse reactions related to disruption of the immune system attributed to denosumab are accumulating. To date

2018 Prescrire

12. Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness

Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness | CADTH.ca Find the information you need Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Denosumab versus Zoledronic Acid for Adults with Osteoporosis: A Review of Cost-Effectiveness Published on: December 12, 2016 Project Number: RC0829-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the cost-effectiveness of denosumab versus zoledronic acid in patients with osteoporosis? Key Message Two studies were identified that evaluated the cost-effectiveness of denosumab for the treatment of elderly men with osteoporosis, from a payer perspective in the United States or Sweden. Both studies found that subcutaneous denosumab 60 mg administered once every six months was associated with lower-costs

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines

Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines | CADTH.ca Find the information you need Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Last updated: August 22, 2019 Project Number (...) : RA1059-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical evidence for varying treatment duration and courses of bisphosphonates for osteoporosis? What are the evidence-based guidelines regarding length of treatment with bisphosphonates for osteoporosis? Key Message One health technology assessment, six systematic reviews (one with meta-analyses), three randomized controlled trials, and five non-randomized studies were identified

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

14. Osteoporosis: Diagnosis, Treatment and Fracture Prevention

Osteoporosis: Diagnosis, Treatment and Fracture Prevention Osteoporosis: Diagnosis, Treatment and Fracture Prevention - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend theme_data_collection data_frontend Data theme_5_collection theme_5_frontend (...) theme_10_collection theme_10_frontend Sports, Recreation, Arts & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Osteoporosis: Diagnosis, Treatment and Fracture Prevention Effective Date: May 1, 2011 Revised: October 1, 2012 Recommendations and Topics Scope Osteoporosis (OP) is a significant risk factor

2013 Clinical Practice Guidelines and Protocols in British Columbia

15. Prevention and treatment of osteoporosis in women

Prevention and treatment of osteoporosis in women Prevention and treatment of osteoporosis in women | British Menopause Society Search for: Summary consensus statement Prevention and treatment of osteoporosis in women Prevention and treatment of osteoporosis in women 2018-11-09T17:16:44+01:00 Summary The British Menopause Society Council aims to aid health professionals to inform and advise women about post reproductive health. Osteoporosis affects 1 in 3 women. This guidance regarding (...) oestrogen and non oestrogen based treatments for osteoporosis responds to the controversies about the benefits and risks of individual agents. Treatment choice should be based on up to date evidence based information and targeted to individual women’s needs. Summary practice points HRT reduces the risk of both spine and hip as well as other osteoporotic fractures. Oestrogen remains the treatment of choice for osteoporosis prevention in menopausal women, and especially in those with premature ovarian

2018 British Menopause Society

17. Osteoporosis Prevention, Diagnosis, and Therapy

Osteoporosis Prevention, Diagnosis, and Therapy Cover 1 49,896 Osteoporosis 3/6/01, 10:56 AM 51 NIH Consensus Statement Volume 17, Number 1 March 27–29, 2000 Osteoporosis Prevention, Diagnosis, and Therapy NATIONAL INSTITUTES OF HEALTH Office of the Director Cover 2 49,896 Osteoporosis 3/6/01, 10:14 AM 52 About the NIH Consensus Development Program NIH Consensus Development Conferences are convened to evalu­ ate available scientific information and resolve safety and efficacy issues related (...) that are part of the public session, and (3) closed deliberations by the panel during the remain­ der of the second day and morning of the third. This statement is an independent report of the consensus panel and is not a policy statement of the NIH or the Federal Government. Reference Information For making bibliographic reference to this consensus statement, it is recommended that the following format be used, with or without source abbreviations, but without authorship attribution: Osteoporosis

2000 NIH Consensus Statements

18. Osteoporosis

Osteoporosis Osteoporosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteoporosis Last reviewed: February 2019 Last updated: October 2018 Summary Asymptomatic until fracture occurs. Diagnosis based on history of prior fragility fracture or low bone mineral density, which is defined as a T-score ≤-2.5. Screening is based on individual risk factors, including female sex, maternal history of fragility fracture (...) /osteoporosis, older age, low body mass index (<20 to 25 kg/m²), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease. Fall prevention is first-line therapy. Bisphosphonates are first-line pharmacological therapy for postmenopausal women and men. In postmenopausal women, oestrogen is considered only for those at high risk for whom non-oestrogen medicines

2018 BMJ Best Practice

19. Bisphosphonates for treating osteoporosis

Bisphosphonates for treating osteoporosis Bisphosphonates for treating Bisphosphonates for treating osteoporosis osteoporosis T echnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Bisphosphonates for treating osteoporosis (TA464) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 25Contents Contents 1 Recommendations 4 2 The technologies 7 3 Committee discussion 9 Nature of the condition 9 Clinical management of the condition 9 Assessing

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

20. American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis ARTHRITIS & RHEUMATOLOGY Vol. 69, No. 8, August 2017, pp 1521–1537 DOI 10.1002/art.40137 V C 2017, American College of Rheumatology SPECIAL ARTICLE 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis Lenore Buckley, 1 Gordon Guyatt, 2 Howard A. Fink, 3 Michael Cannon, 4 Jennifer Grossman, 5 Karen E. Hansen, 6 Mary (...) . Results. Because of limited evidence regarding the benefits and harms of interventions in GC users, most recommendationsinthisguideline areconditional (uncertain balance between benefits and harms). Rec- ommendations include treating only with calcium and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication(oralbisphosphonatepreferred)inadultsat moderate-to-high fracturerisk,continuing calcium plus

2017 American College of Rheumatology